Stay updated on AVA6000 in Solid Tumours Clinical Trial
Sign up to get notified when there's something new on the AVA6000 in Solid Tumours Clinical Trial page.

Latest updates to the AVA6000 in Solid Tumours Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange Detected- Revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check22 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 with no changes to core study content or page data.SummaryDifference0.0%

- Check44 days agoChange DetectedThe study page appears unchanged in core content such as eligibility criteria and locations; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check51 days agoChange DetectedAdded details of the Phase 1a 3+3 dose-escalation design for AVA6000 with Q3W and Q2W schedules and the Phase 1b dose expansion with an RDE-1 cohort to identify the optimal biologic dose. It also notes AVA6000 as a FAP-activated doxorubicin and updates the cardiac safety assessment to include cumulative exposure to doxorubicin.SummaryDifference1%

- Check58 days agoChange DetectedAdded a site-wide notice about government funding status and NIH CC operations, and updated CMS to version v3.4.1. The previous CMS version v3.4.0 was removed.SummaryDifference0.4%

- Check65 days agoChange DetectedAdds a glossary display and new study-record metadata fields: Last Update Submitted that Met QC Criteria and Last Update Posted, along with No FEAR Act Data and a Revision: v3.4.0 note. Removes older QC-related labels (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4) and, to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to AVA6000 in Solid Tumours Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AVA6000 in Solid Tumours Clinical Trial page.